Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis
- 13 June 2015
- journal article
- research article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 32 (6) , 555-566
Abstract
The isoprenoid biosynthetic pathway (IBP) is critical for providing substrates for the post-translational modification of proteins key in regulating malignant cell properties, including proliferation, invasion, and migration. Inhibitors of the IBP, including statins and nitrogenous bisphosphonates, are used clinically for the treatment of hypercholesterolemia and bone disease respectively. The statins work predominantly in the liver, while the nitrogenous bisphosphonates are highly sequestered to bone. Inhibition of the entire IBP is limited by organ specificity and side effects resulting from depletion of all isoprenoids. We have developed a novel compound, disodium [(6Z,11E,15E)-9-[bis(sodiooxy)phosphoryl]-17-hydroxy-2,6,12,16-tetramethyheptadeca-2,6,11,15-tetraen-9-yl]phosphonate (GGOHBP), which selectively targets geranylgeranyl diphosphate synthase, reducing post-translational protein geranylgeranylation. Intracardiac injection of luciferase-expressing human-derived 22Rv1 PCa cells into SCID mice resulted in tumor development in bone (100 %), adrenal glands (72 %), mesentery (22 %), liver (17 %), and the thoracic cavity (6 %). Three weeks after tumor inoculation, daily subcutaneous (SQ) injections of 1.5 mg/kg GGOHBP or the vehicle were given for one month. Dissected tumors revealed a reduction in adrenal gland tumors corresponding to a 54 % (P < 0.005) reduction in total adrenal gland tumor weight of the treated mice as compared to vehicle-treated controls. Western blot analysis of the harvested tissues showed a reduction in Rap1A geranylgeranylation in adrenal glands and mesenteric tumors of the treated mice while non-tumorous tissues and control mice showed no Rap1A alteration. Our findings detail a novel bisphosphonate compound capable of preferentially altering the IBP in tumor-burdened adrenal glands of a murine model of PCa metastasis.Keywords
This publication has 71 references indexed in Scilit:
- Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cellsLeukemia Research, 2011
- Statin medication use and the risk of biochemical recurrence after radical prostatectomyCancer, 2010
- Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasisOncogene, 2009
- Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude miceBMC Cancer, 2008
- Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate CancerMolecular Endocrinology, 2008
- Assessing Tumor Growth and Distribution in a Model of Prostate Cancer Metastasis using Bioluminescence ImagingClinical & Experimental Metastasis, 2005
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005
- Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer ModelClinical Cancer Research, 2004
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Differential Effects of Monoterpenes and Lovastatin on RAS ProcessingJournal of Biological Chemistry, 1995